BioNTech grows in cell therapies, buying Kite’s TCR platformBioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 Share XBioNTech grows in cell therapies, buying Kite’s TCR platformhttps://pharmaphorum.com/news/biontech-grows-in-cell-therapies-buying-kites-tcr-platform/
Gilead combs Shoreline for NK cell therapies in $2.3bn allianceGilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging Share XGilead combs Shoreline for NK cell therapies in $2.3bn alliancehttps://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus dataNovartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Share XASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus datahttps://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyIn 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the Share XAllogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyhttps://pharmaphorum.com/news/allogene-announces-pivotal-trial/
Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
Gilead’s Kite gains some height after second CAR-T approval in USGilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in Share XGilead’s Kite gains some height after second CAR-T approval in UShttps://pharmaphorum.com/news/gileads-kite-gains-some-height-after-second-car-t-approval-in-us/
Gilead closes in on second CAR-T approval in USThe FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Share XGilead closes in on second CAR-T approval in UShttps://pharmaphorum.com/news/gilead-closes-in-on-second-car-t-approval-in-us/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
